This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
November 18, 2013 /PRNewswire/ --
Collaboration aims to use QIAGEN's companion diagnostic development capabilities to create a companion diagnostic paired with a novel oncology compound from Lilly
New partnership builds on Lilly-QIAGEN framework agreement for development of advanced diagnostic tests to guide treatment with innovative therapies
Third project follows success of FDA-approvedtherascreenKRAS test in metastatic colorectal cancer and clinical development of JAK2 genetic test in blood cancers
QIAGEN (NASDAQ: QGEN;
Frankfurt, Prime Standard: QIA) today announced an agreement with Eli Lilly and Company (NYSE: LLY) to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic information in patient samples to enable personalized decisions on treatments. The latest collaboration, involving an undisclosed Lilly compound and an undisclosed molecular diagnostic target, builds on a master collaboration agreement for development of tailored therapies in cancer and other therapeutic areas signed earlier this year.
QIAGEN and Lilly are long-standing partners in personalized healthcare. QIAGEN's
therascreen® KRAS RGQ PCR Kit has been widely adopted by laboratories since its
July 2012 approval by the Food and Drug Administration (FDA) as a companion diagnostic. The
therascreen KRAS Test detects gene mutations in metastatic colorectal cancer patients, indicating which ones will benefit from Erbitux. In
September 2011, QIAGEN and Lilly partnered to develop a companion diagnostic that evaluates the Janus kinase 2 (JAK2) gene, which plays a role in some blood cancers. The test is paired with a Lilly compound to guide use of the proposed drug, currently in clinical trials.
"We are pleased to partner with Lilly on a third development program to improve life for cancer patients through companion diagnostics that guide the use of novel targeted medications. QIAGEN is a preferred partner for leading pharmaceutical companies like Lilly because our validated development processes and regulatory track record provide an accelerated path to commercialization," said
Peer Schatz, QIAGEN's Chief Executive Officer. "Using standardized, well-validated processes to develop and commercialize companion diagnostics reduces the risks in drug development for Pharma companies. Once approved, our
therascreen tests have a ready path to commercial adoption since laboratories around the world have embraced QIAGEN's efficient QIAsymphony automation platform."
"Partnering with QIAGEN on this program enables Lilly to continue to advance our goal of providing tailored therapies to patients in need," said
Daniel Skovronsky, M.D., Ph.D., vice president, tailored therapeutics, Lilly and CEO, Avid Radiopharmaceuticals, Lilly's wholly owned molecular imaging subsidiary. "The QIAGEN and Lilly teams have formed strong working relationships and we look forward to working with QIAGEN to advance this latest innovation together."
The Lilly co-development program and others are designing companion diagnostics that offer laboratories an efficient workflow on QIAGEN's Rotor-Gene Q MDx instrument using real-time PCR technology. The Rotor-Gene Q MDx is part of the QIAsymphony family of automated platforms.